Top

Published in:

01-04-2015 | Maternal-Fetal Medicine

The effect of inherited thrombophilia on second trimester combined aneuploidy screening test markers

Authors: Muzaffer Seyhan Cıkman, Kerem Doga Seckin, Mehmet Fatih Karslı, Eralp Baser, Duygu Ilke Cıkman, Mahmut Nedim Cicek

Published in: Archives of Gynecology and Obstetrics | Issue 4/2015

Abstract

Purpose

To determine whether inherited thrombophilia affects components of second trimester combined aneuploidy screening test.

Methods

A case–control study was performed between 1 December 2010 and 1 February 2012, at a tertiary referral hospital. Singleton pregnancies with inherited thrombophilia that underwent second trimester (16–19⁺⁶ week) combined aneuploidy screening test were included in the study. Maternal serum alfa fetoprotein, unconjugated estriol, human chorionic gonadotropin levels and multiple of median (MoM) levels were compared between the study group and controls.

Results

Within the study period, 18,943 women with singleton pregnancies had a combined second trimester aneuploidy screening test at our institution. Among these, 26 women met the criteria of thrombophilia. A control group that comprised 275 women with similar gestational age was generated, using a 1:1 ratio. Unconjugated estriol MoM levels were significantly lower in women with inherited thrombophilia (p = 0.02). But there was no statistically significant difference for unconjugated estriol levels, human chorionic gonadotropin, alfa fetoprotein and their MoM levels.

Conclusions

Our study suggest that in patients with hereditary thrombophilia a new correction factor should be used, when calculating unconjugated estriol MoM value, which is one of the markers of second trimester aneuploidy screening test.

Saller DN Jr, Canick JA (2008) Current methods of prenatal screening for Down syndrome and other fetal abnormalities. Clin Obstet Gynecol 51(1):24–36CrossRefPubMed

Bogart M, Pandian MR, Jones OW (1987) Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 7(9):623–630CrossRefPubMed

Canick JA, Knight GJ, Palomaki GE et al (1988) Low second trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome. Br J Obstet Gynecol 95(4):330–333CrossRef

Wenstrom KD (2005) First trimester down syndrome screening: component analytes and timing for optimal performance. Semin Perinat 29(4):195–202CrossRef

Stella CL, Sibai B (2006) Thrombophilia and adverse maternal-perinatal outcome. Clin Obstet Gynecol 49(4):850–860CrossRefPubMed

Vinatier D, Dufour P, Cosson M, Houpeau JL (2001) Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 96(1):37–50CrossRefPubMed

Brenner B, Sarig G, Wainer Z et al (1999) Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Hemostas 82(1):6–9

Brochet C, Morin N, Coudert M et al (2009) Impact of antiphospholipid biology in maternal Down syndrome screening. Prenat Diagn 29(5):481–488CrossRefPubMed

Irwin JC, Suen LF, Martina NA et al (1999) Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod 14(2):90–96CrossRefPubMed

10.

Spencer K, Yu CK, Cowans NJ et al (2005) Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 25(10):949–953CrossRefPubMed

11.

Derbent AU, Yanik FF, Inegöl Gümüş I et al (2012) Impact of inherited thrombophilias on first and second trimester maternal serum markers for aneuploidy. J Matern Fetal Neonatal Med 25(11):2177–2181CrossRefPubMed

12.

Gagnon A, Wilson RD, Audibert F et al (2008) Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 30(10):918–949PubMed

13.

Frank M, Maymon R, Wiener Y et al (2013) The effect of hereditary versus acquired thrombophilia on triple test Down’s syndrome screening. Prenat Diagn 33(2):191–195CrossRefPubMed

14.

Brochet C, Morin N, Coudert M et al (2009) Impact of antiphospholipid biology in maternal Down syndrome screening. Prenat Diagn 29(5):481–488CrossRefPubMed

15.

Yaron Y, Cherry M, Kramer RL et al (1999) Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181(4):968–974CrossRefPubMed

16.

Shenhav S, Gemer O, Sassoon E et al (2002) Mid-trimester triple test levels in early and late onset severe pre-eclampsia. Prenat Diagn 22(7):579–582CrossRefPubMed

Title: The effect of inherited thrombophilia on second trimester combined aneuploidy screening test markers
Authors: Muzaffer Seyhan Cıkman
Kerem Doga Seckin
Mehmet Fatih Karslı
Eralp Baser
Duygu Ilke Cıkman
Mahmut Nedim Cicek
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 4/2015
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-014-3468-1

At a glance: The STEP trials

Springer Medicine

The effect of inherited thrombophilia on second trimester combined aneuploidy screening test markers

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Erratum to: The effect of inherited thrombophilia on second trimester combined aneuploidy screening test markers

Patient safety and adverse events related with obstetric care

Emergency peripartum hysterectomy in a tertiary teaching hospital: a 14-year review

What should be the goal for future development of colposcopy? Cons and pros of sensitivity and specificity

Comparison of tissue prolidase enzyme activity and serum oxidative stress level between pregnant women with placental abruption and those with a healthy pregnancy

Response to: Predictors of success of laparoscopic ovarian drilling in women with polycystic ovary syndrome; an evidence-based approach